Consequently, cyclin D1–expressing MCL cells, particularly those with concomitant ATM deficiency, are vulnerable to POLΘ inhibition, unveiling a potential biomarker-driven treatment option for this patient population. This evidence concerns the gene ATM and mantle cell lymphoma.